ReviewNanoscale advances2026
Nanomaterial-enabled methods for nucleic-acid sensing: biorecognition, transduction, comparative evidence, and translational considerations.
Review in Nanoscale advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early and accurate detection of nucleic acids, particularly DNA, is central to modern diagnostics, environmental surveillance, and biomedical research. Nanomaterial-enabled nucleic-acid biosensors exploit nanoscale physicochemical properties, including high surface-area-to-volume ratio, tunable optical responses, enhanced electron transfer, magnetic enrichment, and catalytic activity, to improve sensitivity, selectivity, response time, and device miniaturization. This review examines nanomaterial-enabled DNA and RNA sensing, distinguishing recognition, amplification, and reporting functions. The principal biorecognition elements, including enzymes, antibodies, nucleic-acid probes, aptamers, and peptides, are discussed, followed by transduction strategies such as surface-enhanced Raman spectroscopy, amperometric, potentiometric, field-effect, conductometric, and impedimetric electrochemical biosensors, and electrical immunosensors. The roles of key nanomaterials, including gold nanoparticles, iron oxide nanoparticles, quantum dots, and graphene, are reviewed as signal-amplification and transduction components. Representative studies are evaluated in terms of limit of detection, linear range, selectivity, and clinical applicability. Because assay conditions differ among studies, reported detection limits are considered together with the sample matrix, amplification method, and validation approach. Particular emphasis is placed on linking material properties, recognition chemistry, and readout mechanisms to practical diagnostic performance. Finally, current challenges, multiplexed quantification, clinical translation, and emerging nanofabrication strategies for next-generation biosensors for point-of-care use are highlighted. This article is a critical narrative review; the databases, exact search strings, eligibility criteria, screening procedure and record counts used to assemble the surveyed corpus are reported, and a study-level inventory is provided in the SI.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.